Vero Cell Media Market Size was valued at USD 0.86 Billion in 2022 and is projected to grow from USD 0.99 Billion in 2023 to USD 3.42 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.71% during the forecast period (2023 - 2032). Growing consumer desire for media free of animal components and serum, increasing consumer interest for biosimilars and monoclonal antibodies, and growth of the biotechnology and pharmaceutical sectors are the key market drivers enhancing the market growth.
Growing consumer desire for media free of animal components and serum is driving the market growth
The increased consumer demand for products free of animal components and serum is causing a fundamental upheaval in the worldwide biopharmaceuticals and vaccine production landscape. The market for Vero cell media is being greatly impacted by this paradigm shift, which is forcing players in the market to innovate and adapt to consumers' shifting tastes.
In the past, animal-derived ingredients like fetal bovine serum (FBS) have been added to cell culture media in order to supply the vital nutrients, growth hormones, and proteins needed for cell division and growth. But the need for alternatives has grown as a result of worries about possible pollutants, moral issues surrounding the use of animals in research, and the possibility of adding unidentified variables into the production process. Media formulations without animal components and without serum are becoming more and more in demand from consumers, regulatory bodies, and biopharmaceutical businesses.
The demand from consumers for more moral and open business practices is having a big impact on the Vero mobile media sector in a number of ways. Above all, it is driving a surge of research and development aimed at developing innovative formulations that can sustain strong Vero cell growth and high viral product outputs without requiring ingredients derived from animals. This includes figuring out synthetic or plant-based substitutes for nutrients and growth hormones obtained from serum.
Regulations have also changed as a result of the shift toward Vero cell medium free of serum and animal components. Regulatory bodies are concentrating more and more on making sure biopharmaceutical products are safe and consistent. Part of this effort involves closely examining the ingredients used in their manufacture. In answer to this problem, the media sector has designed its products to be both legally compliant and compliant with customer preferences, sustainability, and animal welfare.
From a business standpoint, organizations now have more ways to stand out from the competition and obtain a competitive advantage due to the growing demand for Vero cell media free of animal components and serum. Those leading the charge in creating and promoting these cutting-edge media formulations are well-positioned to seize a sizeable portion of the market and satisfy the demands of biopharmaceutical companies looking to implement more ethical and sustainable production methods. Thus, driving the Vero cell media market revenue.
The Vero Cell Media Market segmentation, based on type, includes Epithelial and Internal. The Epithelial segment dominated the market in 2022. Vero cells and other epithelial cells are frequently employed in the manufacturing of vaccines. They are especially useful for spreading viruses that are used to create vaccines. Vero cell media are consistently in demand due to the continued need for vaccinations, particularly those for developing infectious illnesses and the seasonal flu.
The Vero Cell Media Market segmentation, based on Application, includes Scientific Research and Industrial Production. The Scientific Research category generated the most income in 2022. Vero cells are commonly employed in virology research to study many viruses, including newly emerging infectious illnesses. Viral outbreaks, like the COVID-19 pandemic, are a constant concern, thus efficient research tools, like Vero cell medium, are crucial for understanding virus-host interactions, viral replication, and the development of antiviral drugs and vaccines.
Figure 1: Vero Cell Media Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Vero Cell Media Market dominated this market in 2022 (45.80%). North America has an advanced and well-developed biopharmaceutical industry, with the United States leading the way. Many biotech and pharmaceutical companies involved in vaccine manufacture, biologics manufacturing, and virology research are based in this region. Because these enterprises are so well-established, there is a huge demand for Vero cell media. Further, the U.S. Vero cell media market held the largest market share, and the Canada Vero cell media market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: VERO CELL MEDIA MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Vero cell media market accounts for the second-largest market share. To guarantee the quality and safety of biopharmaceutical goods, European nations uphold strict regulatory norms. Vero cell media that satisfy these characteristics are highly sought after since they are necessary to adhere to legal regulations. Further, the German Vero cell media market held the largest market share, and the UK Vero cell media market was the fastest growing market in the European region.
The Asia-Pacific Vero Cell Media Market is expected to grow at the fastest CAGR from 2023 to 2032. A number of Asia-Pacific nations, including China and India, have made significant strides in the biopharmaceutical manufacturing industry. To support their expanding biotech sectors, these nations have made significant investments in bioprocessing infrastructure and knowledge, including the creation of Vero cell medium. Moreover, China’s Vero cell media market held the largest market share, and the Indian Vero cell media market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Vero cell media market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Vero cell media industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Vero cell media industry to benefit clients and increase the market sector. In recent years, the Vero cell media industry has offered some of the most significant advantages to medicine. Major players in the Vero cell media market, including Biological Industries, Sigma Aldrich, Mindray Medical International Limited, Boster Bio, Arcomed AG, Hospira Inc, Dickinson, Lonza, Serana Bio, Terumo Medical Corporation and others, are attempting to increase market demand by investing in research and development operations.
Lonza Group Ltd. (Lonza) is a provider of development and contract manufacturing solutions. Clinical development, production, and commercial mammalian and microbial manufacturing are among the services it provides. The company provides a range of services and goods including high-potential active pharmaceutical components, cell and gene therapy capabilities, advanced intermediates, cell-culture modeling, genome editing, endotoxin products, research media, and testing products.
Lonza offers solutions for composites and material protection, microbiological and hygienic control, and health and well-being. Lonza provides services to formulators, service providers, makers of consumer and health products, and research organizations in the biotechnology, pharmaceutical, academic, and government sectors. The corporation has operations in the Americas, Europe, and Asia for manufacturing and research and development. Based in Basel, Switzerland, is Lonza's headquarters.
Terumo Corp. (Terumo) manufactures and markets equipment as well as supplies for hospitals and medical facilities. Some of the company's primary product categories include pharmaceuticals, blood bags, disposable medical equipment, nutritional food supplements, cardiovascular systems, vascular grafts, blood glucose monitoring systems, medical electronics, peritoneal dialysis, and digital thermometers. Applications for these technologies include the delivery of medications inside blood arteries as well as cardiac and vascular procedures.
Furthermore, Terumo operates blood centers where blood is extracted and processed to fulfill transfusion requirements for patients. Through subsidiaries and linked companies, the company has operations throughout China, Japan, Europe, North America, South America, Asia Pacific, the Middle East, and Africa. The Terumo headquarters are situated in Shibuya-ku, Tokyo, Japan.
Key Companies in the Vero cell Media Market Include
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.86 Billion |
| Market Size 2023 | USD 0.99 Billion |
| Market Size 2032 | USD 3.42 Billion |
| Compound Annual Growth Rate (CAGR) | 14.71% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Biological Industries, Sigma Aldrich, Mindray Medical International Limited, Boster Bio, Arcomed AG, Hospira Inc, Dickinson, Lonza, Serana Bio, Terumo Medical Corporation |
| Key Market Opportunities | ·        Increasing consumer interest for biosimilars and monoclonal antibodies |
| Key Market Dynamics | ·        The growth of the biopharmaceutical sector fuels the demand for Vero cell media for cell culture applications. |
Frequently Asked Questions (FAQ) :
The Vero Cell Media Market size was valued at USD 0.87 Billion in 2022.
The global market is projected to grow at a CAGR of 14,71% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Biological Industries, Sigma Aldrich, Mindray Medical International Limited, Boster Bio, Arcomed AG, Hospira Inc, Dickinson, Lonza, Serana Bio, Terumo Medical Corporation.
The Epithelial category dominated the market in 2022.
The Scientific Research had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
